{
    "guideline_identifier": "PIIS0923753425000596.txt",
    "cancer_focus": {
        "primary_cancer": "Peripheral T-cell lymphomas (PTCLs) and natural killer (NK) cell lymphomas",
        "related_syndrome_or_condition": ""
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "All subtypes",
            "risk_group": "General",
            "treatment_plans": [
                {
                    "clinical_context": "Multidisciplinary team discussion",
                    "recommendation_type": "Standard care",
                    "recommendation_content": "MDT discussion for all patients",
                    "treatment_line": "Diagnostic",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I, A"
                },
                {
                    "clinical_context": "Staging workup",
                    "recommendation_type": "Diagnostic",
                    "recommendation_content": "PET-CT preferred for nodal/extranodal PTCLs; BM biopsy mandatory",
                    "treatment_line": "Diagnostic",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I, A"
                }
            ]
        },
        {
            "staging_criteria": "Nodal PTCL (PTCL-NOS/TFHL)",
            "risk_group": "Advanced/High-risk",
            "treatment_plans": [
                {
                    "clinical_context": "First-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "CHOP or CHOEP",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II, B"
                },
                {
                    "clinical_context": "Consolidation",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Auto-HSCT for high-risk/advanced disease",
                    "treatment_line": "Consolidation",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III, B"
                }
            ]
        },
        {
            "staging_criteria": "Systemic ALCL",
            "risk_group": "ALK-positive",
            "treatment_plans": [
                {
                    "clinical_context": "First-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "BV-CHP ×6 cycles or CHOEP",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "CD30",
                            "status": "Positive",
                            "testing_guidance": "IHC required"
                        },
                        {
                            "name": "ALK",
                            "status": "Positive",
                            "testing_guidance": "FISH/IHC for translocation"
                        }
                    ],
                    "esmo_evidence_level": "I, A"
                }
            ]
        },
        {
            "staging_criteria": "Systemic ALCL",
            "risk_group": "ALK-negative",
            "treatment_plans": [
                {
                    "clinical_context": "First-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "BV-CHP ×6 cycles",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "CD30",
                            "status": "Positive",
                            "testing_guidance": "IHC required"
                        }
                    ],
                    "esmo_evidence_level": "I, A"
                },
                {
                    "clinical_context": "Consolidation",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Auto-HSCT",
                    "treatment_line": "Consolidation",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II, B"
                }
            ]
        },
        {
            "staging_criteria": "BIA-ALCL",
            "risk_group": "Stage IA-IC",
            "treatment_plans": [
                {
                    "clinical_context": "Localized disease",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Total capsulectomy",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "CD30",
                            "status": "Positive",
                            "testing_guidance": "IHC confirmation"
                        }
                    ],
                    "esmo_evidence_level": "III, A"
                }
            ]
        },
        {
            "staging_criteria": "BIA-ALCL",
            "risk_group": "Advanced",
            "treatment_plans": [
                {
                    "clinical_context": "Advanced disease",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "BV-CHP or CHOP",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "CD30",
                            "status": "Positive",
                            "testing_guidance": "IHC required"
                        }
                    ],
                    "esmo_evidence_level": "III, A"
                },
                {
                    "clinical_context": "Consolidation",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "ISRT for residual disease; Auto-HSCT",
                    "treatment_line": "Consolidation",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III, B"
                }
            ]
        },
        {
            "staging_criteria": "ENKTCL",
            "risk_group": "Limited Stage",
            "treatment_plans": [
                {
                    "clinical_context": "First-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Radiotherapy (≥50 Gy) + L-asparaginase-based chemotherapy",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "EBV DNA",
                            "status": "Detected",
                            "testing_guidance": "PCR monitoring in blood"
                        }
                    ],
                    "esmo_evidence_level": "II, A"
                }
            ]
        },
        {
            "staging_criteria": "ENKTCL",
            "risk_group": "Advanced",
            "treatment_plans": [
                {
                    "clinical_context": "First-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "DDGP or AspMetDex",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "EBV DNA",
                            "status": "Detected",
                            "testing_guidance": "PCR monitoring in blood"
                        }
                    ],
                    "esmo_evidence_level": "III, B"
                },
                {
                    "clinical_context": "Consolidation",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Auto/allo-HSCT for high-risk patients",
                    "treatment_line": "Consolidation",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III, B"
                }
            ]
        },
        {
            "staging_criteria": "HSTCL",
            "risk_group": "All stages",
            "treatment_plans": [
                {
                    "clinical_context": "First-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "ICE or IVAC (non-CHOP regimens)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "IV, B"
                },
                {
                    "clinical_context": "Consolidation",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Allo-HSCT preferred",
                    "treatment_line": "Consolidation",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III, A"
                }
            ]
        },
        {
            "staging_criteria": "T-PLL",
            "risk_group": "All stages",
            "treatment_plans": [
                {
                    "clinical_context": "First-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Alemtuzumab",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III, A"
                },
                {
                    "clinical_context": "Consolidation",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Allo-HSCT in CR",
                    "treatment_line": "Consolidation",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III, B"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed/Refractory Nodal/Extranodal PTCL",
            "risk_group": "Chemosensitive",
            "treatment_plans": [
                {
                    "clinical_context": "Salvage therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Platinum-based salvage (ICE/DHAP) → Allo-HSCT",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II, B"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed/Refractory ALK+ ALCL",
            "risk_group": "BV-refractory",
            "treatment_plans": [
                {
                    "clinical_context": "Targeted therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "ALK inhibitors (alectinib/ceritinib)",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [
                        {
                            "name": "ALK",
                            "status": "Positive",
                            "testing_guidance": "FISH/IHC confirmation at relapse"
                        }
                    ],
                    "esmo_evidence_level": "III, A"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "CD30 predicts BV efficacy; EBV DNA load prognostic in ENKTCL; ALK translocation directs ALK inhibitor use; TCR clonality confirms malignancy; Genetic markers (RHOA, IDH2, TET2) aid subtyping and targeted therapy selection"
    }
}